Experimental cell therapy takes on tough blood cancers
NCT ID NCT04629729
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called FT819 for people with B-cell cancers (lymphoma, CLL, or B-ALL) that have not responded to standard therapies. The goal is to find a safe dose and see if the therapy can shrink tumors. About 54 participants will receive FT819 alone or with another drug (IL-2) to boost its effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Florida
Jacksonville, Florida, 32224, United States
-
Mayo Minnesota
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Norton Cancer Institute, St. Matthews Campus
Louisville, Kentucky, 40207, United States
-
Oregon Health & Sciences University
Portland, Oregon, 97239, United States
-
Scripps Green Hospital
La Jolla, California, 92037, United States
-
Stanford Cancer Institute
Palo Alto, California, 94304, United States
-
The University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
-
UC Davis
Davis, California, 95817, United States
-
UCLA Ronald Reagan Medical Center
Los Angeles, California, 90095, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of Florida
Gainesville, Florida, 32608, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Wisconsin-Madison
Madison, Wisconsin, 53705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a single shot build a cancer army inside the body?
- Can a Two-Drug combo wipe out hidden leukemia cells?